Cargando…

Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative

Significant numbers of malignant tumor cells that have spread to surrounding tissues and other distant organs are often too small to be picked up in a diagnostic test, and prevention of even such small metastases should improve patient outcomes. Using a mouse model, we show in this article that intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Liqiu, Kambe, Ryosuke, Tsuchiya, Tomoko, Kanegasaki, Shiro, Takahashi, Akihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895898/
https://www.ncbi.nlm.nih.gov/pubmed/31717914
http://dx.doi.org/10.3390/cancers11111770
_version_ 1783476657860902912
author Ma, Liqiu
Kambe, Ryosuke
Tsuchiya, Tomoko
Kanegasaki, Shiro
Takahashi, Akihisa
author_facet Ma, Liqiu
Kambe, Ryosuke
Tsuchiya, Tomoko
Kanegasaki, Shiro
Takahashi, Akihisa
author_sort Ma, Liqiu
collection PubMed
description Significant numbers of malignant tumor cells that have spread to surrounding tissues and other distant organs are often too small to be picked up in a diagnostic test, and prevention of even such small metastases should improve patient outcomes. Using a mouse model, we show in this article that intravenous administration of a human CCL3 variant carrying a single amino acid substitution after mild local hyperthermia not only induces tumor growth inhibition at the treated site but also inhibits metastasis. Colon26 adenocarcinoma cells (1 × 10(5) cells/mouse) were grafted subcutaneously into the right hind leg of syngeneic BALB/c mice and after nine days, when tumor size reached ~11 mm in diameter, the local tumor mass was exposed to high-frequency waves, by which intratumoral temperature was maintained at 42 °C for 30 min. Mice received the CCL3 variant named eMIP (2 μg/mouse/day) intravenously for five consecutive days starting one day after heat treatment. We found that tumor growth in eMIP recipients after hyperthermia was inhibited markedly but no effect was seen in animals treated with either hyperthermia or eMIP alone. Furthermore, the number of lung metastases evaluated at 18 days after hyperthermia treatment was dramatically reduced in animals receiving the combination therapy compared with all other controls. These results encourage future clinical application of this combination therapy.
format Online
Article
Text
id pubmed-6895898
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68958982019-12-24 Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative Ma, Liqiu Kambe, Ryosuke Tsuchiya, Tomoko Kanegasaki, Shiro Takahashi, Akihisa Cancers (Basel) Article Significant numbers of malignant tumor cells that have spread to surrounding tissues and other distant organs are often too small to be picked up in a diagnostic test, and prevention of even such small metastases should improve patient outcomes. Using a mouse model, we show in this article that intravenous administration of a human CCL3 variant carrying a single amino acid substitution after mild local hyperthermia not only induces tumor growth inhibition at the treated site but also inhibits metastasis. Colon26 adenocarcinoma cells (1 × 10(5) cells/mouse) were grafted subcutaneously into the right hind leg of syngeneic BALB/c mice and after nine days, when tumor size reached ~11 mm in diameter, the local tumor mass was exposed to high-frequency waves, by which intratumoral temperature was maintained at 42 °C for 30 min. Mice received the CCL3 variant named eMIP (2 μg/mouse/day) intravenously for five consecutive days starting one day after heat treatment. We found that tumor growth in eMIP recipients after hyperthermia was inhibited markedly but no effect was seen in animals treated with either hyperthermia or eMIP alone. Furthermore, the number of lung metastases evaluated at 18 days after hyperthermia treatment was dramatically reduced in animals receiving the combination therapy compared with all other controls. These results encourage future clinical application of this combination therapy. MDPI 2019-11-11 /pmc/articles/PMC6895898/ /pubmed/31717914 http://dx.doi.org/10.3390/cancers11111770 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ma, Liqiu
Kambe, Ryosuke
Tsuchiya, Tomoko
Kanegasaki, Shiro
Takahashi, Akihisa
Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title_full Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title_fullStr Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title_full_unstemmed Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title_short Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative
title_sort anti-metastatic benefits produced by hyperthermia and a ccl3 derivative
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895898/
https://www.ncbi.nlm.nih.gov/pubmed/31717914
http://dx.doi.org/10.3390/cancers11111770
work_keys_str_mv AT maliqiu antimetastaticbenefitsproducedbyhyperthermiaandaccl3derivative
AT kamberyosuke antimetastaticbenefitsproducedbyhyperthermiaandaccl3derivative
AT tsuchiyatomoko antimetastaticbenefitsproducedbyhyperthermiaandaccl3derivative
AT kanegasakishiro antimetastaticbenefitsproducedbyhyperthermiaandaccl3derivative
AT takahashiakihisa antimetastaticbenefitsproducedbyhyperthermiaandaccl3derivative